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1. INTRODUCTION {#edm211-sec-0005}
===============

The treatment of type 2 diabetes mellitus (T2DM) aims to maintain glycaemic control by optimizing the drug and dose regimen to prevent long‐term microvascular and macrovascular complications.[1](#edm211-bib-0001){ref-type="ref"} However, the positive impact of tight glycaemic control is counteracted by the negative impact of an increased incidence of hypoglycaemia.[2](#edm211-bib-0002){ref-type="ref"}

Hypoglycaemia is a recognized risk that is associated with the use of a number of treatments for T2DM, particularly insulin and sulfonylureas,[3](#edm211-bib-0003){ref-type="ref"}, [4](#edm211-bib-0004){ref-type="ref"} that can expose patients to potential harmful effects.[5](#edm211-bib-0005){ref-type="ref"} Indeed, the clinical impact of severe hypoglycaemia is substantial, including confusion, seizures, coma or even death.[6](#edm211-bib-0006){ref-type="ref"}, [7](#edm211-bib-0007){ref-type="ref"}, [8](#edm211-bib-0008){ref-type="ref"}, [9](#edm211-bib-0009){ref-type="ref"}, [10](#edm211-bib-0010){ref-type="ref"}, [11](#edm211-bib-0011){ref-type="ref"}

Existing health outcome research on hypoglycaemic events tends to focus on severe events that are reported or treated by clinicians.[12](#edm211-bib-0012){ref-type="ref"} However, most hypoglycaemic events are mild to moderate in nature. There is limited evidence describing the impact of mild‐to‐moderate hypoglycaemia in the current literature; hence, it is likely that the burden of these events may be underestimated. The present study aimed to assess the impact of hypoglycaemic events, by severity, on health‐related quality of life (HRQoL), work productivity loss, healthcare resource use (HCRU) and costs in Europe.

2. MATERIALS AND METHODS {#edm211-sec-0006}
========================

2.1. Patients {#edm211-sec-0007}
-------------

Patients were selected from the 2013 National Health and Wellness Survey (NHWS) conducted in 5 European countries: France, Germany, Italy, Spain and the United Kingdom (UK). The NHWS is an annual, cross‐sectional, Internet‐based survey of demographics, disease status, healthcare attitudes, behaviours and outcomes in adults aged 18 years and older. Sampling of the survey is designed to reflect the population of the surveyed countries. Each year, data on age and gender distributions in each country are obtained from the International Database---a database maintained by the United States Census Bureau. These proportions are then mimicked during the recruitment of panel members through a sampling framework, stratified by age, gender and race/ethnicity, and verified against national health statistics to ensure the final sample matches the demographic composition of the surveyed countries.[13](#edm211-bib-0013){ref-type="ref"} To further ensure a representative sample (particularly in the population aged 65 years and older), the online panel recruitment is supplemented by computer‐assisted web interviews, whereby respondents are recruited over the telephone and given the choice of being interviewed live or receiving a link to the survey via email to complete it on their own.

This study included patients in the NHWS who self‐reported a diagnosis of T2DM and were currently receiving pharmacologic therapy for this condition. Analyses were conducted on the combined data from all 5 countries. Baseline demographic and clinical characteristics included age, gender, marital status (married/living with partner or not‐married), education (university degree or greater versus less than university degree), household income (\<€20 000, €20 000‐50 000, \>€50 000 or decline to answer), body mass index (BMI; underweight, normal, overweight, obese or decline to answer), smoking status (% who currently smoke), alcohol use (% who currently drink), exercise behaviour (% who currently exercise), insulin/sulfonylureas use, duration of diagnosis, HbA1c and comorbidities recorded in the Charlson Comorbidity Index (CCI).[14](#edm211-bib-0014){ref-type="ref"} The CCI weights the presence of the following comorbidities and sums the result, with the total index score representing the comorbid burden: HIV/AIDS, metastatic tumour, lymphoma, leukaemia, any tumour, moderate/severe renal disease, hemiplegia, diabetes, mild liver disease, ulcer disease, connective tissue disease, chronic pulmonary disease, dementia, cerebrovascular disease, peripheral vascular disease, myocardial infarction, chronic heart failure and diabetes with end‐organ damage.

2.2. Assessments {#edm211-sec-0008}
----------------

In this study, the primary independent variable was hypoglycaemic event severity. Respondents were asked whether or not they had experienced a hypoglycaemic event in the previous 3 months, and the type of hypoglycaemic event they experienced. Respondents were categorized into 1 of 3 groups (no event, nonsevere event or severe event) based on their responses. Nonsevere events were described as symptomatic episodes that could be managed by the patient themselves, whereas severe events were episodes that required assistance from a healthcare professional or other person as defined by the American Diabetes Association Workgroup on Hypoglycemia.[5](#edm211-bib-0005){ref-type="ref"} In view of the nature of the survey, respondents were given no additional instructions on how to choose the event that was described and could only select 1 event, even if they had experienced multiple events during the time period of interest.

2.3. Health‐related quality of life {#edm211-sec-0009}
-----------------------------------

Health‐related quality of life was assessed using the Medical Outcomes Study 36‐Item Short Form Survey Instrument version 2 (SF‐36v2).[15](#edm211-bib-0015){ref-type="ref"} The SF‐36v2 is a multipurpose, generic health status instrument comprising 36 questions that map onto 8 health domains: physical functioning, physical role limitations, bodily pain, general health, vitality, social functioning, emotional role limitations and mental health. The relevant scores from these 8 domains are summarized in 2 component scores: the physical component summary (PCS) and the mental component summary (MCS).

Each domain and summary score are calculated using a norm‐based scoring algorithm that allows for all measures to be viewed together and to be interpreted relative to population values. Higher scores represent better health status and a shift in the score of 6‐8.5 for each domain can be considered clinically meaningful.[16](#edm211-bib-0016){ref-type="ref"} The items from the SF‐36v2 can also be used to derive a preference‐based health utility index (SF‐6D) for health economic assessment.[17](#edm211-bib-0017){ref-type="ref"}, [18](#edm211-bib-0018){ref-type="ref"}

Using the SF‐6D classification system, the response pattern of the SF‐36v2 items was converted to a health utility score, which conceptually varies from 0 (a health state equivalent to death) to 1 (a health state equivalent to perfect health), and represents an individual\'s judgement around a variety of concepts related to overall health and quality of life. Previous research suggests that the minimal important difference (MID) for component scores is 3 points, 5 points for the norm‐based domain scores and 0.041 points for the health utilities index.[15](#edm211-bib-0015){ref-type="ref"}, [19](#edm211-bib-0019){ref-type="ref"}, [20](#edm211-bib-0020){ref-type="ref"}

2.4. Work productivity {#edm211-sec-0010}
----------------------

Work productivity was assessed in the subset of patients who reported being in full‐time or part‐time employment using the Work Productivity and Activity Impairment (WPAI) General Health Questionnaire, a validated 6‐item instrument consisting of 4 metrics: absenteeism (the percentage of work time missed because of one\'s health), presenteeism (the percentage of impairment experienced while at work because of one\'s health), overall work productivity loss (an overall impairment estimate as a combination of absenteeism and presenteeism) and activity impairment (the percentage of impairment in daily activities because of one\'s health).[21](#edm211-bib-0021){ref-type="ref"} Only those respondents who reported being employed full‐time or part‐time provided data for absenteeism, presenteeism and overall work impairment, while all respondents provided data for activity impairment. The measures are expressed as a percentage of the time missed in the previous 7 days.

2.5. Healthcare resource use and the costs {#edm211-sec-0011}
------------------------------------------

Healthcare utilization was assessed by a number of variables, including the reported number of traditional healthcare provider visits, the number of Emergency Room (ER) visits, and the number of times the patient were hospitalized in the past 6 months. These data were used in conjunction with information on income and the average cost of medical services to estimate the average direct costs associated with HCRU, and indirect costs associated with lost productivity.

Unit costs were derived from the Medical Expenditure Panel Survey (MEPS) database[22](#edm211-bib-0022){ref-type="ref"} and are presented as 2013 €. Indirect costs associated with lost productivity were calculated from the number of hours missed due to absenteeism and the number of hours missed due to presenteeism multiplied by the associated hourly wage, and this amount annualized.[23](#edm211-bib-0023){ref-type="ref"}, [24](#edm211-bib-0024){ref-type="ref"}, [25](#edm211-bib-0025){ref-type="ref"}, [26](#edm211-bib-0026){ref-type="ref"} The final estimates represent the total costs of HCRU for participants over the prior year.

2.6. Statistical analyses {#edm211-sec-0012}
-------------------------

Descriptive statistics are reported as means and standard deviations for continuous variables and percentages for discrete variables. Ordinary least squares regression models were used for SF‐36 measures, and negative binomial regressions with log‐link distributions were used for WPAI measures. The following demographic and health characteristics were used as covariates in the multivariate regression models: age, gender, insulin/sulfonylureas use, smoking, CCI, diagnosis length, number of diabetic complications and HbA1c. In addition, a sensitivity analysis was conducted using an expanded list of covariates in a regression model of the SF‐6D utilities, including age, gender, insulin/sulfonylureas use, smoking, diagnosis length, HbA1c, exercise, depression, stroke, transient ischaemic attack, myocardial infarction, congestive heart failure, peripheral arterial disease, chronic kidney disease, chronic liver disease, peripheral vascular disease, cerebrovascular disease, dementia and diabetic complications (foot/leg ulcer, kidney disease, macular oedema/diabetic retinopathy, neuropathic pain and diabetes with end‐organ damage). In all regression models, the trend in mean values was tested for statistical significance (*P *\<* *.05).

3. RESULTS {#edm211-sec-0013}
==========

3.1. Study population {#edm211-sec-0014}
---------------------

A total of 1269 patients met the inclusion criteria, of whom 652 (51.4%) had not experienced a hypoglycaemic event, 533 (42.0%) had experienced a nonsevere hypoglycaemic event and 84 (6.6%) had experienced a severe hypoglycaemic event in the past 3 months.

3.2. Patient baseline characteristics {#edm211-sec-0015}
-------------------------------------

Patient characteristics by country are shown in Table [1](#edm211-tbl-0001){ref-type="table"} and by severity of hypoglycaemic event in Table [2](#edm211-tbl-0002){ref-type="table"}. Additional demographic data stratified by severity of hypoglycaemic events by country, are presented in Tables [S1‐S5](#edm211-sup-0001){ref-type="supplementary-material"}; the proportion of patients taking insulin, sulfonylureas, either insulin or sulfonylureas, insulin only and sulfonylureas by severity of hypoglycaemia is presented in Table [S6](#edm211-sup-0001){ref-type="supplementary-material"}. While patient characteristics were generally similar among countries, regression analysis of the total study population identified a significant trend for patients who experienced a severe hypoglycaemic event to be younger (mean age 60.7, 59.2 and 56.2 years for no event, nonsevere event and severe event, respectively; *P *=* *.001) and to have a higher comorbidity burden (mean CCI 0.67, 0.71 and 1.74, respectively; *P *\<* *.001; Table [2](#edm211-tbl-0002){ref-type="table"}). On average, patients who experienced a severe hypoglycaemic event also had a higher rate of kidney disease, neuropathic pain and macular oedema or diabetic retinopathy relative to other groups (*P *\<* *.05; Table [2](#edm211-tbl-0002){ref-type="table"}). Insulin use was higher in the nonsevere and severe groups relative to those who did not experience a hypoglycaemic event (55.7%, 58.3% and 36.8%, respectively; *P *\<* *.001), while sulfonylureas use did not differ significantly among these groups (Table [2](#edm211-tbl-0002){ref-type="table"}).

###### 

Study population demographics by country

  \% (n), unless otherwise stated                 France (n = 266)   Germany (n = 401)   Italy (n = 130)   Spain (n = 121)   UK (n = 351)
  ----------------------------------------------- ------------------ ------------------- ----------------- ----------------- --------------
  Age, yrs (mean, SD)                             60.5 (10.6)        59.8 (11.4)         63.7 (12.4)       60.7 (10.6)       57.4 (12.1)
  Sex                                                                                                                        
  Female                                          32 (85)            32 (129)            49 (64)           23 (28)           40 (140)
  Male                                            68 (181)           68 (272)            51 (66)           77 (93)           60 (211)
  BMI, kg/m^2^ (mean, SD)                         30.4 (6.3)         31.1 (6.1)          28.3 (5.7)        29.4 (4.3)        32.1 (7.4)
  Currently smoke                                 14.3 (38)          26.2 (105)          22.3 (29)         28.1 (34)         20.5 (72)
  Currently drink                                 71.4 (190)         68.8 (276)          50.8 (66)         72.7 (88)         73.8 (259)
  Currently exercise                              48.9 (130)         44.6 (179)          47.7 (62)         58.7 (71)         40.5 (142)
  CCI (mean, SD)                                  0.75 (2.21)        0.87 (1.39)         0.72 (1.21)       0.74 (1.15)       0.67 (1.15)
  Rate of hypoglycaemia severity within country                                                                              
  No event                                        53.4 (142)         54.6 (219)          53.1 (69)         47.1 (57)         47 (165)
  Nonsevere event                                 40.2 (107)         39.7 (159)          40.0 (52)         45.5 (55)         45.6 (160)
  Severe event                                    6.4 (17)           5.7 (23)            6.9 (9)           7.4 (9)           7.4 (26)

BMI, body mass index; CCI, Charlson Comorbidity Index; SD, standard deviation; UK, United Kingdom.

John Wiley & Sons, Ltd

###### 

Total study population demographics by severity of hypoglycaemia

  \% (n), unless otherwise stated          No hypoglycaemic event (n = 652)   Nonsevere event (n = 533)   Severe event (n = 84)   *P*‐value
  ---------------------------------------- ---------------------------------- --------------------------- ----------------------- -----------
  Age, yrs (mean, SD)                      60.7 (11.4)                        59.3 (11.1)                 56.2 (14.7)             .001
  Sex                                                                                                                             .131
  Female                                   32.7 (213)                         38.3 (204)                  34.5 (29)               
  Male                                     67.3 (439)                         61.7 (329)                  65.5 (55)               
  BMI, kg/m^2^ (mean, SD)                  30.8 (6.6)                         30.7 (5.9)                  30.6 (8.6)              .918
  Currently smoke                          20.4 (133)                         21.4 (114)                  36.9 (31)               .014
  Currently drink                          69.2 (451)                         69.4 (370)                  69.0 (58)               .995
  Currently exercise                       46.6 (304)                         45.0 (240)                  47.6 (40)               .821
  CCI (mean, SD)                           0.67 (1.17)                        0.71 (1.23)                 1.74 (3.66)             \<.001
  Duration of diabetes, yrs (mean, SD)     12.2 (8.7)                         13.5 (9.7)                  10.9 (7.5)              .006
  Complications                                                                                                                   
  Foot or leg ulcer                        6.6 (43)                           7.1 (38)                    11.9 (10)               .207
  Kidney disease                           6.9 (45)                           8.4 (45)                    23.8 (20)               \<.001
  Macular oedema or diabetic retinopathy   8.6 (56)                           15.0 (80)                   10.7 (9)                .002
  Neuropathic pain                         13.2 (86)                          19.5 (104)                  25.0 (21)               .002
  Diabetes with end‐organ damage           3.7 (24)                           3.4 (18)                    9.5 (8)                 .024
  None of these                            71.0 (463)                         63.8 (340)                  47.6 (40)               \<.001
  Use of insulin                           36.8 (240)                         55.7 (297)                  58.3 (49)               \<.001
  Use of sulfonylureas                     22.7 (148)                         24.6 (131)                  15.5 (13)               .177

BMI, body mass index; CCI, Charlson Comorbidity Index; SD, standard deviation.

John Wiley & Sons, Ltd

3.3. Health‐related quality of life {#edm211-sec-0016}
-----------------------------------

After controlling for covariates, increasing severity of hypoglycaemia was inversely associated with mean health utility scores (0.64, 0.62 and 0.58 for no event, nonsevere and severe groups, respectively; *P *\<* *.001; Figure [1](#edm211-fig-0001){ref-type="fig"}). Health utility scores were similar to those previously reported for patients with T2DM receiving basal‐bolus insulin therapy (0.68 for patients without hypoglycaemia, and 0.60 for those with severe hypoglycaemia).[27](#edm211-bib-0027){ref-type="ref"} The robustness of the regression model was confirmed by the consistent results of the sensitivity analysis (0.6371, 0.6212 and 0.5877 for no event, nonsevere and severe groups, respectively).

![Health utilities and overall mental and physical component summary scores of the SF‐36 by severity of hypoglycaemic event. SF‐36, 36‐Item Short‐Form Health Survey](EDM2-1-e00011-g001){#edm211-fig-0001}

A similar pattern was observed for MCS and PCS scores across no event, nonsevere and severe groups (mean MCS scores: 45.1, 43.5 and 40.5, respectively, *P *=* *.002; mean PCS scores: 42.2, 41.3 and 38.7, respectively, *P *=* *.008; Figure [1](#edm211-fig-0001){ref-type="fig"}). The differences in MCS, PCS and health utilities between patients who experienced no hypoglycaemia event compared with those who experienced a severe hypoglycaemic event exceeded the MID threshold. Increased severity of hypoglycaemia was also associated with a significant decrease in all individual SF‐36 subscales, except for General Health (*P *\<* *.05; Figure [2](#edm211-fig-0002){ref-type="fig"}).

![SF‐36 domain scores by severity of hypoglycaemia.^a^ SF‐36, 36‐Item Short‐Form Health Survey. aData presented are the results of multivariate regression analysis controlling for covariates](EDM2-1-e00011-g002){#edm211-fig-0002}

3.4. Work productivity {#edm211-sec-0017}
----------------------

A total of 395 (31.1%) employed participants completed the WPAI (no event: 204; nonsevere: 163; severe: 20). Although increased severity of hypoglycaemia was associated with increased overall activity impairment (Figure [3](#edm211-fig-0003){ref-type="fig"}), no significant differences were observed in absenteeism, presenteeism or overall work impairment.

![Work productivity (WPAI‐GH) scores by severity of hypoglycaemia.^a^ WPAI‐GH, Work Productivity and Activity Impairment---General Health. aData are a percentage of time missed in the last 7 d for employed participants](EDM2-1-e00011-g003){#edm211-fig-0003}

3.5. Healthcare resource utilization and direct costs {#edm211-sec-0018}
-----------------------------------------------------

Regression analyses showed that an increase in severity of hypoglycaemia was associated with an increase in HCRU (Table [3](#edm211-tbl-0003){ref-type="table"}), with the mean number of both ER visits and hospitalizations increasing significantly with the severity of hypoglycaemia (*P *\<* *.001; Table [3](#edm211-tbl-0003){ref-type="table"}). This also resulted in significantly higher direct costs of healthcare practitioner and ER visits, as well as hospitalizations (*P *\<* *.001; Table [4](#edm211-tbl-0004){ref-type="table"}). The indirect cost associated with presenteeism was also significantly greater with increased severity of hypoglycaemia (*P *=* *.003), but there was no difference in the cost associated with absenteeism between the groups.

###### 

Healthcare resource utilization in the past 6 months by severity of hypoglycaemia[a](#edm211-note-0004){ref-type="fn"}

  Mean (95% CI)      No hypoglycaemic event (n = 652)   Nonsevere event (n = 533)   Severe event (n = 84)   *P*‐value
  ------------------ ---------------------------------- --------------------------- ----------------------- -----------
  HCP visits         9.04 (8.22, 9.94)                  9.72 (8.73, 10.82)          12.66 (9.78, 16.38)     .036
  ER visits          0.22 (0.17, 0.27)                  0.25 (0.20, 0.32)           1.03 (0.72, 1.47)       \<.001
  Hospitalizations   0.18 (0.14, 0.23)                  0.12 (0.09, 0.16)           0.66 (0.44, 0.98)       \<.001

CI, confidence interval; ER, emergency room; HCP, healthcare practitioner.

Data presented are the results of multivariate regression analysis controlling for covariates.

John Wiley & Sons, Ltd

###### 

Direct and indirect costs (€) by severity of hypoglycaemia[a](#edm211-note-0006){ref-type="fn"}

  Mean (SD)          No hypoglycaemic event (n = 652)   Nonsevere event (n = 533)   Severe event (n = 84)   *P*‐value
  ------------------ ---------------------------------- --------------------------- ----------------------- -----------
  Direct (€)                                                                                                
  HCP                531.16 (538.00)                    587.79 (570.50)             1011.64 (1728.25)       \<.001
  ER                 67.66 (292.09)                     78.05 (216.02)              368.87 (787.52)         \<.001
  Hospitalizations   424.60 (1436.36)                   323.16 (1150.10)            2376.68 (5877.27)       \<.001
  Total              1023.42 (1707.62)                  989.01 (1427.06)            3757.18 (7545.38)       \<.001
  Indirect (€)                                                                                              
  Absenteeism        1737.26 (5116.70)                  2491.69 (6051.31)           3310.36 (6243.94)       .234
  Presenteeism       4027.81 (4745.04)                  3641.03 (4590.87)           7139.68 (6192.67)       .003
  Total              5626.86 (7227.42)                  5887.00 (7451.60)           9940.06 (10 950.73)     .019

ER, emergency room; HCP, healthcare practitioner; SD, standard deviation.

Data presented are the results of multivariate regression analysis controlling for covariates.

John Wiley & Sons, Ltd

4. DISCUSSION {#edm211-sec-0019}
=============

To our knowledge, this is the first study that evaluates the association between severity of hypoglycaemia and a comprehensive set of patient outcomes (eg, HRQoL, productivity loss, HCRU and costs) conducted in 5 European countries utilizing a nationally representative sample by age and gender. It differs from most other studies of hypoglycaemia in that it investigates the relative impact of nonsevere and severe hypoglycaemia, whereas previous studies have mainly focused on severe hypoglycaemia. Overall, hypoglycaemia was shown to have a significant impact on HRQoL as well as on HCRU and costs.

Almost half of the patients analysed in this study (42%) reported experiencing a hypoglycaemic event in the 3 months prior to completing the survey. Of these patients, only 7% reported experiencing a severe hypoglycaemic event, suggesting that the majority of hypoglycaemic events in adult patients with T2DM were nonsevere in nature. These observations are consistent with previous studies, which report that nonsevere hypoglycaemic events occur in 24%‐60% of patients with diabetes, accounting for 88% of all hypoglycaemic events,[28](#edm211-bib-0028){ref-type="ref"} and have a substantial impact on productivity,[28](#edm211-bib-0028){ref-type="ref"} emotional and social functioning, diabetes management, sleep and decreased well‐being.[29](#edm211-bib-0029){ref-type="ref"}, [30](#edm211-bib-0030){ref-type="ref"}, [31](#edm211-bib-0031){ref-type="ref"}

A statistically significant association between insulin use and the severity of hypoglycaemic events (consistent with the drug\'s side‐effect profile) was observed in this study. This observation is consistent with the outcomes of the HAT study in patients with T1DM or T2DM treated with insulin (conducted in 24 countries), which reported an association between the rate of hypoglycaemia and an increased duration of diabetes and insulin therapy.[32](#edm211-bib-0032){ref-type="ref"} There was no significant association between the severity of hypoglycaemic events and the use of sulfonylureas, with very low numbers in the severe subgroup (n = 13) precluding any meaningful interpretation (Tables [S1](#edm211-sup-0001){ref-type="supplementary-material"}, [S2](#edm211-sup-0001){ref-type="supplementary-material"} and [S5](#edm211-sup-0001){ref-type="supplementary-material"}). It is plausible that patients taking sulfonylureas experience more nonsevere events that severe events, unlike patients taking insulin.

Although the regression model utilized controlled for a number of the covariates, to account for any potential influence on outcomes, further stratification by different age groups or duration of diabetes in future research may be insightful.

Our study found that an increase in severity of hypoglycaemia was associated with a significant and clinically relevant decrement in both physical and mental health component of HRQoL and overall health utility. Previous studies conducted in the UK, United States, Canada and Brazil have also shown self‐reported hypoglycaemic symptoms to be independently associated with reduced HRQoL,[12](#edm211-bib-0012){ref-type="ref"}, [33](#edm211-bib-0033){ref-type="ref"}, [34](#edm211-bib-0034){ref-type="ref"}, [35](#edm211-bib-0035){ref-type="ref"} and that the magnitude of this reduction increases with both the severity and frequency of the symptoms.[8](#edm211-bib-0008){ref-type="ref"}, [35](#edm211-bib-0035){ref-type="ref"}, [36](#edm211-bib-0036){ref-type="ref"} A recent study also demonstrated a significant relationship between experiencing low blood sugar symptoms and decreased HRQoL, decreased utility and greater difficulties with mobility, daily activities, pain/discomfort and anxiety/depression, relative to patients who did not report those symptoms.[12](#edm211-bib-0012){ref-type="ref"}

These results are of considerable importance due to the notable humanistic and economic burden associated with hypoglycaemic events. The present study builds on the current literature by demonstrating the impact that the severity of hypoglycaemia has on this burden, but showing that even nonsevere events impose a considerable burden on patient outcomes and resource use. In addition, the increased severity of hypoglycaemia was also associated with an increase in activity impairment in this patient population. This increase is notable, as the group with no hypoglycaemic events also reported a higher degree of activity impairment than that shown in the general population.[37](#edm211-bib-0037){ref-type="ref"}

Our study also showed that increasing severity of hypoglycaemia was associated with an increase in HCRU, which resulted in higher estimated direct medical costs. A previous analysis indicated that the direct and indirect costs associated with a hypoglycaemic event increased with severity, with the indirect costs associated with nonsevere hypoglycaemia, severe hypoglycaemia requiring medical assistance and severe hypoglycaemia requiring nonmedical assistance predicted to be US\$11, US\$176 and US\$579, respectively, for patients with T2DM.[38](#edm211-bib-0038){ref-type="ref"} Hypoglycaemic events requiring medical assistance were associated with a high economic burden (US\$1161 per episode in T1DM and T2DM patients) compared with events requiring nonmedical assistance and those managed by self‐treatment (US\$66 and US\$11, respectively). Hospital treatment of severe events was also shown to be a major cost in Germany, Spain and the UK, with average treatment costs being higher for patients with T2DM (Germany, €533; Spain, €691; UK, €537) than those with T1DM (€441, €577 and €236, respectively).[39](#edm211-bib-0039){ref-type="ref"}

4.1. Limitations {#edm211-sec-0020}
----------------

The current results should be considered within the context of several limitations. The NHWS is a patient‐reported, cross‐sectional, web‐based survey, and the data were not verified against clinicians' diagnoses or chart reviews, nor were reports of low blood sugar confirmed by blood glucose monitoring. Moreover, the cross‐sectional nature of the analysis does not allow a for inference on the causation of the results nor the temporal association.[8](#edm211-bib-0008){ref-type="ref"} Due to the nature of the survey design, patients with hypoglycaemia were able to report only 1 hypoglycaemic event experienced in the previous 3 months, but may have experienced multiple events over that time period; hence, the true impact of the events may be underreported. In addition, almost half of patients surveyed were on insulin (Table [2](#edm211-tbl-0002){ref-type="table"}), which was associated with the reporting of hypoglycaemic events. Yet, the recent legislation in the UK---whereby individuals taking insulin are required to report this information to the transport authorities---may have affected the responses in this country, leading to an underestimation of the number of severe hypoglycaemic events (a smaller proportion of patients in the UK compared with France and Germany reported these events; Tables [S1](#edm211-sup-0001){ref-type="supplementary-material"}, [S2](#edm211-sup-0001){ref-type="supplementary-material"} and [S5](#edm211-sup-0001){ref-type="supplementary-material"}, respectively).

Overall, the results of this study show that the impact of hypoglycaemia on patient outcomes varies by severity, and that both severe and nonsevere events are associated with decreased HRQoL and higher HCRU. This study highlights the importance of managing hypoglycaemia to enable the most favourable glycaemic control and avoid the increased humanistic and economic burden related to these events.
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